To establish the clinical relevance of increased PIM1/GSK3β signaling in mediating acquired resistance to osimertinib in NSCLC, we obtained CT images of three cases of advanced EGFR-mutant lung adenocarcinoma. The gene discussed is GSK3B; the disease is non-small cell lung carcinoma.